On November 25, 2024 Nerviano Medical Sciences S.r.l. (NMS), a clinical stage company discovering and developing innovative therapies for the treatment of cancer, reported that it has successfully negotiated with Merck KGaA the buy back of the full world-wide rights of NMS-293 (also known as NMS-03305293) (Press release, Nerviano Medical Sciences, NOV 25, 2024, View Source [SID1234648614]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NMS-293 is a potent, highly selective PARP1 inhibitor designed to avoid trapping, a known cause of toxicity in healthy cells, making it ideal for combination with DNA-damaging agents like chemotherapies, or ADC payloads, including in homologous recombination repair proficient tumors. In this respect, initial safety data across the program have shown high bone marrow tolerability1, supporting future promising clinical combinations in solid tumors.

Hugues Dolgos, Pharm.D., Chief Executive Officer, NMS commented: "The agreement that we announce today allows Nerviano Medical Sciences to re-gain full control of NMS-293, an innovative potential treatment for cancer patients, which we believe offers opportunity beyond the ongoing phase 2 study in patients with relapsed glioblastoma. We thank our partner Merck KGaA for the excellent collaboration. Our team is actively preparing two phase 1/2 trials to explore solid tumors, which will be subject to a further communication"